Acute rhabdomyolysis as a complication of paclitaxel–gemcitabine chemotherapy for ovarian cancer - ScienceDirect

European Journal of Obstetrics & Gynecology and Reproductive Biology

Volume 145, Issue 2, August 2009, Page 226

European Journal of Obstetrics & Gynecology and Reproductive Biology

https://doi.org/10.1016/j.ejogrb.2009.04.029 Get rights and content

References (5)

A. Ceribelli et al.
Severe rhabdomyolysis associated with permetrexed-based chemotherapy
Lancet Oncol
(2006)
S. Hoshi et al.
Severe rhabdomyolysis as a complication of high-dose chemotherapy in a patient with advanced testicular cancer
Int J Urol
(1999)

There are more references available in the full text version of this article.

Cited by (7)

Neuromuscular complications of SARS-CoV-2 infection—Part 2: muscle disorders
2021, Nervenarzt
Delayed rhabdomyolysis with paclitaxel, ifosfamide, carboplatin, and etoposide regimen: a case report
2017, Journal of Medical Case Reports
A rare adverse effect while treating lung adenocarcinoma
2015, Pneumon
Gemcitabine: Molecular pharmacology, pharmacogenetics and adverse reaction profile
2014, Gemcitabine: Pharmacology, Clinical Uses and Potential Side Effects
Severe acute rhabdomyolysis induced by multi-agent chemotherapy for alveolar rhabdomyosarcoma in a 15-year-old female: A case report
2013, Case Reports in Oncology
A Substrate pharmacophore for the human organic cation/carnitine transporter identifies compounds associated with rhabdomyolysis
2012, Molecular Pharmaceutics

View all citing articles on Scopus

Copyright © 2009 Published by Elsevier Ireland Ltd.